文献速递肿瘤 PET/CT核素与放射性配体治疗

68Ga-FAPI-04 PET/MR与18F-FDG PET/CT在胰腺癌患者中诊断效能的比较

Comparison of the diagnostic efficacy of 68 Ga-FAPI-04 PET/MR and 18F-FDG PET/CT in patients with pancreatic cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-03-04

前瞻性纳入33例疑似胰腺腺癌患者,32例经组织病理学证实、1例经穿刺活检及糖皮质激素治疗证实为自身免疫性胰腺炎,每例均在1周内完成68Ga-FAPI-04 PET/MR与18F-FDG PET/CT检查。两种方法对原发肿瘤检出率均为100%;68Ga-FAPI-04 PET对淋巴结转移检出更多(42 vs 30),18F-FDG PET对肝转移检出更多(181 vs 104)。

要点

  • 68Ga-FAPI-04 PET/MR与18F-FDG PET/CT对原发肿瘤检出率均为100%。
  • 68Ga-FAPI-04 PET检出阳性淋巴结多于18F-FDG PET(42 vs 30,p<0.001)。
  • 18F-FDG PET检出肝转移多于68Ga-FAPI-04(181 vs 104,p<0.001),MR多序列可解释胰腺炎症摄取并检出更多肝转移(256 vs 181)。

核心结论

  • 68Ga-FAPI-04 PET在检测可疑淋巴结转移方面可能优于18F-FDG PET。
  • 68Ga-FAPI-04 PET/MR的MR多序列成像有助于解释梗阻性炎症患者的胰腺病灶并检测微小肝转移。

研究设计与样本

  • 前瞻性评估33例疑似胰腺腺癌患者,其中32例经组织病理学证实,1例经穿刺活检及糖皮质激素治疗证实为自身免疫性胰腺炎。
  • 每例患者在1周内均接受68Ga-FAPI-04 PET/MR和18F-FDG PET/CT检查。
  • 比较两种影像方法对原发肿瘤、淋巴结和转移灶的检测能力,并测量和比较配对病灶在两种检查上的原始SUVmax和归一化SUVmax(SUVmax/SUVbkgd)。

主要发现

  • 共纳入30例胰腺癌患者和3例胰腺炎患者。
  • 68Ga-FAPI-04 PET/MR与18F-FDG PET/CT对原发肿瘤的检出率均为100%。
  • 原发肿瘤在68Ga-FAPI-04 PET上的原始/归一化SUVmax显著高于18F-FDG(p<0.05)。
  • 16例胰腺癌患者有胰腺实质摄取,而18F-FDG PET图像仅显示4例有实质摄取(53.33% vs 13.33%,p<0.001)。
  • 68Ga-FAPI-04 PET检出阳性淋巴结多于18F-FDG PET(42 vs 30,p<0.001),而18F-FDG PET检出肝转移多于68Ga-FAPI-04(181 vs 104,p<0.001);MR多序列成像帮助解释10例因68Ga-FAPI-04炎症摄取而无法明确显示的胰腺癌,并检出肝转移多于18F-FDG(256 vs 181,p<0.001)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We sought to assess the performance of 68 Ga-FAPI-04 PET/MR for the diagnosis of primary tumours as well as metastatic lesions in patients with pancreatic cancer and to compare the results with those of 18F-FDG PET/CT. METHODS: Prospectively, we evaluated 33 patients suspected to have pancreatic adenocarcinoma, of whom thirty-two were confirmed by histopathology, and one had autoimmune pancreatitis confirmed by needle biopsy and glucocorticoid treatment. Within 1 week, each patient underwent both 68 Ga-FAPI-04 PET/MR and 18F-FDG PET/CT. Comparisons of the detection abilities for primary tumours, lymph nodes, and metastases were conducted for the two imaging approaches. The original maximum standard uptake values (SUVmax) and normalised SUVmax (SUVmax/SUVbkgd) of paired lesions on 68 Ga-FAPI-04 PET/MR and 18F-FDG PET/CT were measured and compared. RESULTS: Thirty pancreatic cancer patients and three pancreatitis patients were enrolled. 68 Ga-FAPI-04 PET/MR and 18F-FDG PET/CT exhibited equivalent (100%) detection rates for primary tumours. The original/normalised SUVmax of primary tumours on 68 Ga-FAPI-04 PET was markedly higher than that on 18F-FDG (p < 0.05). Sixteen pancreatic cancer patients had pancreatic parenchymal uptake, whereas 18F-FDG PET images showed parenchymal uptake in only four patients (53.33% vs. 13.33%, p < 0.001). 68 Ga-FAPI-04 PET detected more positive lymph nodes than 18F-FDG PET (42 vs. 30, p < 0.001), while 18F-FDG PET was able to detect more liver metastases than 68 Ga-FAPI-04 (181 vs. 104, p < 0.001). In addition, multisequence MR imaging helped explain ten pancreatic cancers that could not be definitively revealed due to 68 Ga-FAPI-04 inflammatory uptake and identified more liver metastases than 18F-FDG (256 vs. 181, p < 0.001). CONCLUSION: 68 Ga-FAPI-04 PET might be better than 18F-FDG PET in the detection of suspicious lymph node metastases. MR multiple sequence imaging of 68 Ga-FAPI-04 PET/MR was helpful for explaining pancreatic lesions in patients with obstructive inflammation and detecting tiny liver metastases.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Zhang Z, Jia G, Pan G, et al. Comparison of the diagnostic efficacy of 68 Ga-FAPI-04 PET/MR and 18F-FDG PET/CT in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging. 2022. PMID: 35243518. doi:10.1007/s00259-022-05729-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。